avapro and cyclosporine
avapro has been researched along with cyclosporine in 14 studies
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dong, Z; Ekins, S; Polli, JE | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liu, G; Pei, Y; Wang, C; Yan, SF | 1 |
| Norman, BH | 1 |
| Bianchetti, MG; Casaulta-Aebischer, C; Fossali, E; Franscini, LM; Pfister, R; Von Vigier, RO | 1 |
| Chander, H; Chander, V; Chopra, K; Singh, D; Tirkey, N | 1 |
| Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H | 1 |
Reviews
3 review(s) available for avapro and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
Topics: Antiviral Agents; B7-H1 Antigen; Biological Products; Drug Repositioning; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HSC70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Nucleocapsid; Oligonucleotides, Antisense; Programmed Cell Death 1 Receptor; Ribonuclease H; RNAi Therapeutics; Toll-Like Receptors; Virus Internalization; Virus Replication | 2017 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
Other Studies
11 other study(ies) available for avapro and cyclosporine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).
Topics: Azetidines; Bayes Theorem; Biphenyl Compounds; Computational Biology; Ezetimibe; Humans; Irbesartan; Organic Anion Transporters, Sodium-Dependent; Structure-Activity Relationship; Symporters; Tetrazoles; United States; United States Food and Drug Administration | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
Topics: Adolescent; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Child; Child, Preschool; Cyclosporine; Drug Interactions; Female; Humans; Hypertension; Immunosuppressive Agents; Irbesartan; Kidney Failure, Chronic; Linear Models; Male; Prospective Studies; Proteinuria; Renal Dialysis; Tetrazoles; Treatment Outcome | 2002 |
Amelioration of cyclosporine nephrotoxicity by irbesartan, A selective AT1 receptor antagonist.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cyclosporine; Immunosuppressive Agents; Irbesartan; Kidney Diseases; Models, Animal; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tetrazoles | 2004 |
Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
Topics: Adolescent; Antihypertensive Agents; Biphenyl Compounds; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Immunosuppressive Agents; Infusions, Intravenous; Irbesartan; Lupus Erythematosus, Systemic; Lupus Nephritis; Nephrotic Syndrome; Prednisolone; Pulse Therapy, Drug; Recurrence; Ribonucleosides; Severity of Illness Index; Tacrolimus; Tetrazoles | 2013 |